## Open Access Full Text Article

CORRIGENDUM

## **PPAR**γ Agonist-Loaded PLGA-PEG Nanocarriers as a Potential Treatment for Alzheimer's Disease: In vitro and in vivo Studies [Corrigendum]

Silva-Abreu M, Calpena AC, Andrés-Benito P, et al. Int J Nanomedicine. 2018;13:5577-5590.

In the published article, there was an error in Figure 6A on page 5585. The image for Rhod-NPs was duplicated by a mislabeling of the image files. A new image for Rhod-NPs has been updated (bottom right). The authors apologize for this error and state that this does not change the quality and scientific conclusions of the article in any way.

The correct Figure 6 is as follows.



**Figure 6 (A)** Images of PGZ-NPs and Rhod-NPs by TEM after 6 hours in the basolateral compartment. (**B**) Permeability of hCMEC/D3, following exposure to 1  $\mu$ g/mLof NPs for 6 hours. TNF $\alpha$ + IFN $\gamma$  (10 ng/mL, for 24 hours) was used as a positive control, increasing endothelial permeability. **Notes:** Each value is the mean of three independent experiments. ns=nonsignificant, \**P*<0.05 by one-way ANOVA and Dunnett's multiple comparison test (n=3). **Abbreviations:** PGZ-NPs, PGZ-loaded nanoparticles; Rhod-NPs, Rhod-nanoparticles; hCMEC/D3, human brain endothelial cell line; TEM, transmission electron microscopy; TNF $_{\alpha}$ , tumor necrosis factor $_{\alpha}$ ; IFN $_{\gamma}$ , interferon; Pe, permeability coefficient.

International Journal of Nanomedicine 2023:18 3641-3642

Received: 17 May 2023 Accepted: 17 May 2023 Published: 3 July 2023 © 2023 Silva-Abreu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. To permission for commercial uses of this work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. To permission for commercial uses of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). In addition, an error by the journal during the preparation of Figure 7 led to the inadvertent creation of duplicate regions in Figure 7C on page 5586. The journal wishes to apologize for this error.

The correct Figure 7 is as follows.



Figure 7 In vivo evaluation of PGZ-NPs.

Notes: (A) Memory performance of treated animals in the two-object recognition test. APP/PSI animals treated with vehicle showed cognitive impairment when compared with wild-type littermates. In contrast, Free-PGZ and PGZ-NPs treatment reduced the memory impairment in APP/PSI mice. (B) Cortical  $A\beta$  burden is not significantly modified in treated APP/PSI mice, in spite of the tendency to decreased deposition in NP-PGZ-treated animals. (C) Representative images of A $\beta$  immunoreactivity in cortical sections of APP/PSI mice chronically treated with Free-PGZ, PGZ-NPs or vehicle. Scale bar=200 µm. Data are expressed as the mean ± SEM. \*\*P<0.01 compared to WT animals. <sup>\$</sup>P<0.05, <sup>\$\$</sup>P<0.01 compared to vehicle group.

Abbreviations: PGZ-NPs, PGZ-loaded nanoparticles; PGZ, pioglitazone; WT, wild-type; VEH, vehicle.

International Journal of Nanomedicine

## **Dove**press

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch<sup>®</sup>, Current Contents<sup>®</sup>/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http:// www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal

https://doi.org/10.2147/IJN.\$421741

3642 🛐 🈏 in 🖪 DovePress

International Journal of Nanomedicine 2023:18